Business Context and Reporting Period
This Form 6-K filing by Sanofi-Aventis covers the month of January 2005, specifically dated January 6, 2005. The report serves to disclose a press release regarding an update to the patent litigation schedule in the United States concerning the company's product Plavix®.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a legal disclosure regarding litigation status and does not contain financial performance data.
Material Changes
The material change disclosed is an update to the schedule of patent litigation in the United States for Plavix®. No financial changes versus prior periods are reported in this text.
Guidance, Outlook, and Risks
Risks and Contingencies: The filing highlights ongoing patent litigation in the United States for Plavix® as a material contingency. The specific nature of the schedule update is detailed in the attached press release (Exhibit 99.1), which is incorporated by reference.
Management Commentary: The filing is signed by Jean-Claude Leroy, Senior Vice President and Chief Financial Officer, confirming the submission of the litigation update.
Key Facts for Investor Verification
- Verify the specific details of the updated patent litigation schedule for Plavix® in the United States by reviewing Exhibit 99.1 (Press Release dated January 6, 2005).
- Confirm the potential impact of this litigation timeline on the commercial exclusivity and revenue projections for Plavix®.
- Note that this filing contains no financial results; investors should refer to the most recent Form 20-F or quarterly reports for financial metrics.